148 related articles for article (PubMed ID: 23916407)
1. A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human.
Wang J; Xia S; Xue W; Wang D; Sai Y; Liu L; Liu X
Eur J Pharm Sci; 2013 Nov; 50(3-4):290-302. PubMed ID: 23916407
[TBL] [Abstract][Full Text] [Related]
2. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.
Wang YH; Jones DR; Hall SD
Drug Metab Dispos; 2004 Feb; 32(2):259-66. PubMed ID: 14744949
[TBL] [Abstract][Full Text] [Related]
3. Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits.
Kim HJ; Choi JS
Biopharm Drug Dispos; 2005 Oct; 26(7):295-300. PubMed ID: 16013069
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of verapamil and norverapamil enantiomers after administration of immediate and controlled-release formulations to humans:evidence suggesting input-rate determined stereoselectivity.
Bhatti MM; Lewanczuk RZ; Pasutto FM; Foster RT
J Clin Pharmacol; 1995 Nov; 35(11):1076-82. PubMed ID: 8626881
[TBL] [Abstract][Full Text] [Related]
5. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil.
Wang YH; Jones DR; Hall SD
Drug Metab Dispos; 2005 May; 33(5):664-71. PubMed ID: 15689501
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil.
Tracy TS; Korzekwa KR; Gonzalez FJ; Wainer IW
Br J Clin Pharmacol; 1999 May; 47(5):545-52. PubMed ID: 10336579
[TBL] [Abstract][Full Text] [Related]
7. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
Chien JY; Lucksiri A; Ernest CS; Gorski JC; Wrighton SA; Hall SD
Drug Metab Dispos; 2006 Jul; 34(7):1208-19. PubMed ID: 16611859
[TBL] [Abstract][Full Text] [Related]
8. Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil.
Choi DH; Shin WG; Choi JS
Eur J Clin Pharmacol; 2008 May; 64(5):445-9. PubMed ID: 18193210
[TBL] [Abstract][Full Text] [Related]
9. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human.
Dadashzadeh S; Javadian B; Sadeghian S
Biopharm Drug Dispos; 2006 Oct; 27(7):329-34. PubMed ID: 16892180
[TBL] [Abstract][Full Text] [Related]
10. Repeated oral rifampicin decreases the jejunal permeability of R/S-verapamil in rats.
Sandström R; Lennernäs H
Drug Metab Dispos; 1999 Aug; 27(8):951-5. PubMed ID: 10421625
[TBL] [Abstract][Full Text] [Related]
11. Achiral and chiral HPLC analysis of norverapamil and its metabolites in microsomal samples.
Brandsteterová E; Wainer IW; Tracy T
Neoplasma; 1999; 46(4):207-11. PubMed ID: 10613599
[TBL] [Abstract][Full Text] [Related]
12. Effects of grapefruit juice and smoking on verapamil concentrations in steady state.
Fuhr U; Müller-Peltzer H; Kern R; Lopez-Rojas P; Jünemann M; Harder S; Staib AH
Eur J Clin Pharmacol; 2002 Apr; 58(1):45-53. PubMed ID: 11956673
[TBL] [Abstract][Full Text] [Related]
13. Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil.
Gupta SK; Atkinson L; Tu T; Longstreth JA
Br J Clin Pharmacol; 1995 Oct; 40(4):325-31. PubMed ID: 8554934
[TBL] [Abstract][Full Text] [Related]
14. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.
Ma B; Prueksaritanont T; Lin JH
Drug Metab Dispos; 2000 Feb; 28(2):125-30. PubMed ID: 10640508
[TBL] [Abstract][Full Text] [Related]
15. The effect of quercetin on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rabbits.
Choi JS; Han HK
J Pharm Pharmacol; 2004 Dec; 56(12):1537-42. PubMed ID: 15563760
[TBL] [Abstract][Full Text] [Related]
16. Effects of liver fibrosis on verapamil pharmacokinetics in rats.
Chen M; Xu D; Hu XL; Wang H
Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):287-94. PubMed ID: 17973928
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride.
Choi JS; Burm JP
Arch Pharm Res; 2005 Apr; 28(4):483-7. PubMed ID: 15918524
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Jacobson TA
Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous quantification of the enantiomers of verapamil and its N-demethylated metabolite in human plasma using liquid chromatography-tandem mass spectrometry.
Hedeland M; Fredriksson E; Lennernäs H; Bondesson U
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 May; 804(2):303-11. PubMed ID: 15081924
[TBL] [Abstract][Full Text] [Related]
20. Enantioselective distribution of verapamil and norverapamil into human and rat erythrocytes: the role of plasma protein binding.
Robinson MA; Mehvar R
Biopharm Drug Dispos; 1996 Oct; 17(7):577-87. PubMed ID: 8894116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
